Bernhard-Nocht-Str. 74, 20359 Hamburg
+4940-42818-367
Studien
Trial EudraCT# Subjects in total Recruitment in time
A multi-centre safety registry for malaria patients treated with Eurartesim™   2 1 subject in 1 month
still ongoing

A Phase 3, Open-Label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis with Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately from a Japanese Encephalitis Vaccine

 

2015-000382-31 102 97 subjects in 2 weeks
Cumulative phase:
5 subjects in 4 weeks

A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions

 

2011-003603-37 108 100 subjects in 11 weeks
Cumulative phase: 8 subjects in 4 weeks

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection
Randomized, observer-blind, placebo-controlled, multicenter, multi-national, Phase III trial in 15.000 subjects

 

2013-000775-32 14 14 subjects in 2 years

A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adults

 

2013-000601-23 126 126 in 2 days

A Phase III, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healthy Subjects Aged ≥10 toPhase III2009-015198-112323 subjects from July 2013 to December 2013 mostly subjects under 18 years old

 

2009-015198-11 23 23 subjects from July 2013 to December 2013 mostly subjects under 18 years old

Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51 (Ixiaro®, Jespect®) in a Pediatric Population in Non-Endemic Countries. Uncontrolled, Phase III Follow-Up Study

 

2010-022266-27 3  

A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Seperately According to 1 or 2 Different Pre-exposure Prophylaxis Schedules to Healthy Adult Subjects

 

2011-005173-23 138 Enrolment period of 3 months;
138 subjects, 12 visits per subject,
1656 total visits in one year

A Phase IIIb, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Selected Travel Vaccines When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults

 

2011-000475-14 78 78 Subjects in 2 weeks

A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2012/2013, when Administered to Adult and Elderly Subjects

 

2011-006277-25 126 126 Subjects in 2 days

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults

 

2011-001333-17 59  

A Phase 3 randomized, double-blind, placebo-controlled study os SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosis in subjects bitten by a tick

 

2011-000117-39 53 53 Subjects from July 2011 to November 2012
(only in 2 seasons)

An Open Label, Uncontrolled Phase 4 Study to Assess the Safety and Imunnogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population

 

2010-018630-52 83 83 Sujects from July 2010 to September 2010

Immunogenicity and safety of the Japanese encephalitis vaccine IC51 (Ixiaro®, Jespect®) in a pediatric population in non-endemic countries. Uncontrolled, open-label phase 3 study

 

2009-015603-10 72 72 Subjects from March 2010 to June 2010

A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travellers’ Diarrhea Vaccine System in Travellers to Latin America

 

2008-008726-75 258 258 Subjects from December 2009 to June 2010

A Randomized, Single-Blind, Dose Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects from 6 Months to 17 Years of Age

 

2009-013672-45 1  

A Randomized, Single-Blind, Dose Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects

 

200-013671-21 54 54 Subjects in 1 day

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted with MF59 (Fluad-H5N1), in Adult and Elderly Subjects

 

2008-003871-32 100 100 Subjects in 2 days

A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (intramuscular and intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant (MF59) admitted to Healthy Elderly Subjects > 65 Years

 

2008-002625-26 31